Sponsored content

Bioelectronic medicine: a new treatment approach

Bioelectronic medicine is on the cusp of becoming a new way to treat disease. The field’s potential to provide new treatment approaches using electric pulses to activate mechanisms in the body has attracted investments from companies including GlaxoSmithKline (GSK) and Google.

Go to the profile of SetPoint Medical
May 04, 2017
2
0
Upvote 2 Comment
Page of
Go to the profile of SetPoint Medical

SetPoint Medical

SetPoint Medical is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. SetPoint’s approach is intended to offer patients and providers an alternative for the treatment of rheumatoid arthritis (RA) and other chronic inflammatory diseases with less risk and cost than drug therapy. SetPoint is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate the body’s natural Inflammatory Reflex, which is intended to produce a potent systemic anti-inflammatory effect. The company has published positive results from a first-in-human open-label proof-of-concept trial in rheumatoid arthritis in Proceedings of the National Academy of Sciences (PNAS) and presented positive results at the American College of Rheumatology meeting. Current investors in the company include Morgenthaler Ventures, NEA, Topspin Partners, Medtronic, GlaxoSmithKline’s Action Potential Venture Capital Limited and Boston Scientific.
7 Contributions
4 Followers
17 Following

Please sign in or register for FREE to comment